JPWO2019233941A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019233941A5
JPWO2019233941A5 JP2020567772A JP2020567772A JPWO2019233941A5 JP WO2019233941 A5 JPWO2019233941 A5 JP WO2019233941A5 JP 2020567772 A JP2020567772 A JP 2020567772A JP 2020567772 A JP2020567772 A JP 2020567772A JP WO2019233941 A5 JPWO2019233941 A5 JP WO2019233941A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pyrazino
tetrahydro
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527041A (ja
JP7374130B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/064323 external-priority patent/WO2019233941A1/en
Publication of JP2021527041A publication Critical patent/JP2021527041A/ja
Publication of JPWO2019233941A5 publication Critical patent/JPWO2019233941A5/ja
Application granted granted Critical
Publication of JP7374130B2 publication Critical patent/JP7374130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567772A 2018-06-05 2019-06-03 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物 Active JP7374130B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2018090004 2018-06-05
CNPCT/CN2018/090004 2018-06-05
EP18193916 2018-09-12
EP18193916.6 2018-09-12
CNPCT/CN2019/086019 2019-05-08
CN2019086019 2019-05-08
PCT/EP2019/064323 WO2019233941A1 (en) 2018-06-05 2019-06-03 Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease

Publications (3)

Publication Number Publication Date
JP2021527041A JP2021527041A (ja) 2021-10-11
JPWO2019233941A5 true JPWO2019233941A5 (hr) 2023-07-11
JP7374130B2 JP7374130B2 (ja) 2023-11-06

Family

ID=66793968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567772A Active JP7374130B2 (ja) 2018-06-05 2019-06-03 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物

Country Status (19)

Country Link
US (1) US20210371432A1 (hr)
EP (1) EP3802539B1 (hr)
JP (1) JP7374130B2 (hr)
KR (1) KR20210018818A (hr)
CN (1) CN112204028B (hr)
AU (1) AU2019280728A1 (hr)
BR (1) BR112020024782A2 (hr)
CA (1) CA3098291A1 (hr)
CL (1) CL2020003065A1 (hr)
CO (1) CO2020014677A2 (hr)
CR (1) CR20200584A (hr)
IL (1) IL279144A (hr)
MA (1) MA52747A (hr)
MX (1) MX2020012827A (hr)
PE (1) PE20210131A1 (hr)
PH (1) PH12020552092A1 (hr)
SG (1) SG11202011137SA (hr)
TW (1) TW202016111A (hr)
WO (1) WO2019233941A1 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230002375A1 (en) * 2019-11-12 2023-01-05 Hoffmann-La Roche Inc. Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
CN114667286A (zh) * 2019-11-19 2022-06-24 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的三氮杂三环类化合物
JP2023502087A (ja) * 2019-11-19 2023-01-20 エフ．ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物
WO2022013136A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease
WO2022022489A1 (zh) * 2020-07-27 2022-02-03 江苏恒瑞医药股份有限公司 吲哚稠环类衍生物、其制备方法及其在医药上的应用
CN114057759B (zh) * 2020-08-07 2023-05-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
CA3200155A1 (en) * 2020-11-26 2022-06-02 Xiaomin Zhang Fused tricyclic compound, preparation method therefor and application thereof in medicine
WO2023025109A1 (zh) * 2021-08-23 2023-03-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
CN114656363A (zh) * 2022-03-28 2022-06-24 南京林业大学 一种钯催化芳香酯类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106276A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
KR102103256B1 (ko) * 2013-10-14 2020-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
SI3889145T1 (sl) * 2015-12-17 2024-05-31 Merck Patent Gmbh 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj
DK3497094T3 (da) * 2016-08-08 2023-05-15 Merck Patent Gmbh Tlr7/8-antagonister og anvendelser deraf

Similar Documents

Publication Publication Date Title
AU2015296322B2 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
AU2014375500B2 (en) Kinase inhibitor and use thereof
BR112021001292A2 (pt) compostos heterobicíclicos para inibir a atividade de shp2
CN110475777B (zh) 用于治疗和预防细菌感染的新吡啶并[2,3-b]吲哚化合物
ES2548532T3 (es) Compuestos de pirrolopirimidina como inhibidores de CDK4/6
JP7374130B2 (ja) 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物
CN105294683A (zh) Cdk类小分子抑制剂的化合物及其用途
JP2011500774A5 (hr)
CN112313228A (zh) 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物
AU2023201522A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016184832A1 (en) Compounds for treating spinal muscular atrophy
JPWO2019233941A5 (hr)
RU2020142969A (ru) СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
EP3623369B1 (en) Novel morpholinyl amine compounds for the treatment of autoimmune disease
JPWO2019197842A5 (hr)
JPWO2020207991A5 (hr)
WO2023104155A1 (zh) E3泛素连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
RU2021131710A (ru) Соединения гексагидро-1h-пиразино[1,2-a]пиразина для лечения аутоиммунного заболевания
JPWO2022013136A5 (hr)
CN112673007A (zh) 用于治疗自身免疫性疾病的吡唑并吡啶胺化合物
TWI854426B (zh) 稠環取代的六員雜環化合物及其製法和用途
WO2024052512A1 (en) Heterocyclic derivatives as janus kinase inhibitors
TW202330525A (zh) 稠環取代的六員雜環化合物及其製法和用途
NZ768960A (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
US20240140954A1 (en) Tricyclic heterocyclic derivatives, compositions and uses thereof